ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

摘要:

Parecoxib, the newest of the cyclo-oxygenase-2 (COX-2) inhibitors, provides highly effective pain relief combined with a significantly better tolerability profile than nonselective NSAIDs. Parecoxib also has a parenteral route of administration, suggesting that this drug should be particularly useful in the management of acute pain during the perioperative period. The latest findings from recent clinical studies demonstrating the clinical potential for this injectable COX-2 inhibitor were presented at the 35th American Society of Health-System Pharmacists Midyear Clinical Meeting [Las Vegas, US; December 2000].

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

摘要:

Researchers reported recently that a new platinum-based molecule, BBR 3464, shows promise in treating patients with advanced cancer whose disease had previously been resistant to typical platinum therapies. At the 2000 International Chemical Congress of Pacific Basin Societies [Honolulu, US; December 2000], Professor Nicholas Farrell from Virginia Commonwealth University, Richmond, US, commented that a number of structurally novel platinum-based drugs are currently in phase I or II trials. The agents display a profile of DNA binding different to that presented by cisplatin, the standard platinum agent.'Most prominent amongst these is the trinuclear compound BBR 3464. This agent displays a unique profile of biological activity and is the first genuinely new platinum agent to enter clinical trials in 30 years',Professor Farrell stated.

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2001

数据来源: ADIS